Our Development Pipeline
TMB-001, topical isotretinoin in Timber’s patented IPEG™ delivery system, is being developed for the treatment of moderate to severe subtypes of Congenital ichthyosis (CI). During Q4 2021, Timber announced positive top line results for its Phase 2b CONTROL Study. Clinically meaningful efficacy with a favorable safety profile demonstrated the potential of TMB-001 to be an important option for the treatment of CI where no FDA-approved treatments are currently available and the options for standard of care is limited. In Q1 2022, Timber received both Breakthrough Therapy Designation and Fast Track Status from the U.S. Food and Drug Administration (FDA) for TMB-001. Timber initiated the Phase 3 ASCEND clinical trial in Q2 2022.
If you are interested in any of Timber’s ongoing clinical research programs, please contact firstname.lastname@example.org.